Orgenesis Inc. Announces Appointment of Senior Leadership
WHITE PLAINS, NY -- (Marketwire) -- 04/03/12 -- Orgenesis Inc. (OTCBB: ORGS) ("Orgenesis" or the "Company"), a development stage company with a novel therapeutic technology dedicated to convert a patient's own liver cells into functional insulin-producing cells as a treatment for diabetes, is pleased to announce its executive leadership team with the appointments of Chief Executive Officer Jacob BenArie MBA, B.Sc., Chief Financial Officer Dov Weinberg CPA, MBA and Chief Science Officer Prof. Sarah Ferber Ph.D.
Prior to joining Orgenesis, Mr. BenArie served for the past 5 years as the CEO of Beta-Stim Ltd, a privately held company that developed a therapy for the treatment of type-2 diabetes. Mr. BenArie also co-founded Beta-Stim and Slender Medical, a developer of innovative ultrasound technology applications, and the Medical Device Design & Manufacturers Israel conference. Mr. BenArie has over 15 years of experience in various management and R&D positions in life science start-up companies. He holds a B.Sc. in electronic engineering and an MBA, both from the Technion - Israel Institute of Technology.
Mr. Weinberg brings to Orgenesis over 11 years of direct experience in the medical device area. He is an owner and president of Weinberg Dalyo Inc., a U.S corporation which renders business development and financial services to companies in the life science industry. Mr. Weinberg serves currently as CFO of QRS systems Inc., Innovate Inc., Mabcure Inc. and NaNaMEd LLC and was the Chief Financial officer of Impulse Dynamics from December 2000 until the beginning of 2009. Prior to that, Mr. Weinberg served for more than 15 years as the CFO of a large industrial multinational public corporation in charge of finance, information systems, and taxation of the company and its worldwide subsidiaries. Mr. Weinberg has been a Certified Public Accountant since 1979 and received an MBA from Bar-Ilan University in 1984 and a B.A. in Economics & Accounting from Tel Aviv University in 1977.
Prof. Sarah Ferber studied biochemistry at the Technion under the supervision of Professor Avram Hershko and Professor Aaron Ciechanover, winners of the 2004 Nobel Prize in Chemistry. She completed a post-doctoral fellowship at the Joslin Diabetes Center at Harvard Medical School. Prof. Ferber's breakthrough discovery suggested that humans carry their own 'stem-cells' throughout adulthood, thus obviating the need for embryonic stem cells for generating an organ in need. Most of the research regarding this discovery was conducted in Prof. Ferber's own lab facilities; the Endocrine Research Lab at the Sheba Medical Center, which currently employs 11 scientists. Prof. Sarah Ferber received TEVA, LINDNER, RUBIN and WOLFSON awards for this research. Prof. Ferber's research work has been funded over the past 10 years by the Juvenile Diabetes Research Foundation (JDRF), the Israel Academy of Science foundation (ISF) and D-Cure, a non-profit organization that promotes and funds scientific research in Israel, aimed at finding a cure and better treatments for diabetes (together, over US$4M).
Orgenesis is pleased to introduce the executive leadership team and invites interested readers to visit our website at www.orgenesis.com to find out more about the Company and its goal to bring about the end of diabetes as we now know it.
Further details of the Company's business, finances, appointments and agreements can be found as part of the Company's continuous public disclosure as a reporting issuer under the Securities Exchange Act of 1934 filed with the Securities and Exchange Commission's ("SEC") EDGAR database. For more information visit: www.orgenesis.com.
About Orgenesis Inc. (OTCBB: ORGS)
Orgenesis is a development stage company with a novel therapeutic technology that employs a molecular and cellular approach directed at converting a patient's own liver cells into functional insulin producing cells, as a treatment for diabetes. The Company believes that converting the diabetic patient's own tissue into insulin-producing cells overcomes the problem of donor shortage and removes the risk of transplant rejection. If successful, this could mean the end of diabetes as we now know it. For more information visit: www.orgenesis.com.
Notice Regarding Forward-Looking Statements
This news release contains "forward-looking statements" which are not purely historical. Such forward-looking statements include, among other things, the expectations of management that AIPC regeneration technology can be developed as therapeutic treatment for diabetes. No assurance can be given that any of the events anticipated by the forward-looking statements will occur or, if they do occur, what benefits the Company will obtain from them. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects and development stage companies. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Investors should refer to the risk factors disclosure outlined in our periodic reports filed from time-to-time with the Securities and Exchange Commission.
On Behalf of the Board
Vered Caplan, Chairperson
Contact: Investor Relations Crescendo Communications, LLC Email: email@example.com Tel: +1-877-560-9060 Web: www.orgenesis.com
Source: Orgenesis Inc.
Released April 3, 2012